Mark Rothera joins Orchard Therapeutics as CEO

10 August 2017
orchard_therapeutics_big

UK and USA-based clinical-stage biotech Orchard Therapeutics today announces the appointment of Mark Rothera as president and chief executive.

Mr Rothera brings 28 years of experience in the biopharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialization. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs.

Until recently Mr Rothera served as chief commercial officer of PTC Therapeutics, where he helped transition the company from a privately funded, USA-based R&D biotech to a public, commercial stage company with a 47 country commercialization footprint. This he achieved by building a global commercialization capability and successfully launching two rare disease therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology